Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Non-inferiority Study of Unresectable Hepatocelluar Carcinoma Receiving Stereotactic Radiotherapy Combined With Hepatic Arterial Chemoembolization Compared With Conversion Hepatectomy

NCT05057104 is registered in ClinicalTrials.gov with Beijing 302 Hospital as lead sponsor.

NCT NCT05057104
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05057104 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Non-inferiority Study of Unresectable Hepatocelluar Carcinoma Receiving Stereotactic Radiotherapy Combined With Hepatic Arterial Chemoembolization Compared With Conversion Hepatectomy
Lead sponsor
Beijing 302 Hospital
Phase
Observational
Overall status
Unknown status
Start date
October 10, 2021
Completion date
December 31, 2024
Enrollment
320 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

conversion, hepatocellular carcinoma non-resectable